[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631765":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":42,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Kidney-Sparing Multimodal Treatment",null,"Participants undergo endoscopic tumor ablation or resection using thulium fiber laser techniques. Participants without confirmed complete tumor resection will receive selective hypofractionated radiotherapy approximately one month after surgery.Postoperative systemic therapy consists of disitamab vedotin administered every three weeks for eight cycles combined with toripalimab administered every three weeks for up to one year.",[13],"Radiation: SBRT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"RADIATION","SBRT","Participants without confirmed complete tumor resection will receive selective hypofractionated radiotherapy approximately one month after surgery.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Xuesong Li, M.D.","CONTACT","+86-15801399116","pineneedle@sina.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Chenghao Tan, M.D.","+86-83572420","tch1olaf@gmail.com",[31],{"facility":32,"status":10,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"Departmeng of Urology, Peking University First Hospital","Beijing","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Xuesong Li","Professor and Chief Physician, Department of Urology, Peking University First Hospital","100631765","multimodal-kidney-sparing-strategy-for-high-risk-upper-tract-urothelial-carcinoma-100631765",false,"NCT07504939","Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma","Evaluating a Kidney-sparing Strategy Combining Endoscopic Surgery, Adjuvant Radiotherapy, and HER2-targeted Antibody-Drug Conjugate in High-risk Upper Tract Urothelial Carcinoma: Study Protocol for a Prospective, Multicenter, Non-randomized Comparative Clinical Trial","Inclusion Criteria\n\nParticipants must meet all of the following criteria:\n\nAge 18 years or older Voluntary participation with written informed consent Pathology indicating upper tract urothelial carcinoma with HER2 at least 1+ expression Clinical stage cT1-T2N0M0 based on imaging evaluation Classified as high-risk upper tract urothelial carcinoma according to European Association of Urology (EAU) criteria Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Adequate renal function with split renal function of the affected kidney ≥10 mL\u002Fmin on renal dynamic scintigraphy Expected life expectancy greater than 24 months Ability and willingness to comply with study procedures and follow-up schedule Exclusion Criteria\n\nParticipants will be excluded if any of the following conditions are present:\n\nInability to tolerate or refusal of kidney-sparing treatment Evidence of advanced disease (≥T3), lymph node metastasis, or distant metastasis Synchronous bladder urothelial carcinoma or other urological malignancies Previous systemic anticancer therapy, including chemotherapy, targeted therapy, immunotherapy, or antibody-drug conjugates Prior radiotherapy involving the urinary tract or retroperitoneal region Severe uncontrolled comorbidities such as cardiovascular, pulmonary, neurological, psychiatric, or systemic diseases Active severe infections requiring systemic antimicrobial therapy Known immune-related disorders requiring long-term immunosuppressive treatment Pregnancy or breastfeeding Known allergy to investigational drugs used in this study Concurrent participation in another therapeutic clinical trial Indeterminate postoperative pathological diagnosis","ALL","18 Years",{"count":56,"type":57},36,"ESTIMATED","OBSERVATIONAL","UTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter. Although this surgery can control the cancer, it permanently reduces kidney function.\n\nEndoscopic treatment can serve as a kidney-sparing approach for low-risk UTUC; however, in high-risk patients, the high rate of upper tract local recurrence after endoscopic treatment remains the primary failure pattern. This study aims to evaluate the efficacy and safety of radiotherapy-involved kidney-sparing treatment for UTUC.\n\nThe main questions this study aims to answer are: Can this multimodal kidney-sparing strategy reduce local recurrence of UTUC compared with endoscopic treatment alone? Participants in the kidney-sparing group will: Undergo endoscopic surgery to remove the tumor; Receive systemic therapy with disitamab vedotin and toripalimab; Receive targeted radiotherapy after surgery.\n\nParticipants will undergo regular follow-up visits, including imaging examinations and endoscopic evaluations, to monitor for recurrence or disease progression.\n\nThe results of this study may help determine whether a multimodal kidney-sparing treatment strategy could become a safe and effective option for selected patients with high-risk UTUC.",[61,62],"Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy","Upper Tract Urothelial Carcinoma",[64,65,66,67,68,69,70,71],"UTUC","Kidney-Sparing Surgery","Endoscopic Treatment","Disitamab Vedotin","Toripalimab","HER2-Targeted Therapy","Radiotherapy","Multimodal Therapy","NOT_YET_RECRUITING","2026-04-21",{"date":75,"type":76},"2026-04-24","ACTUAL",{"date":78,"type":57},"2026-04-01",{"date":80,"type":57},"2030-04-01",{"name":5,"class":6},1]